Health
Why Might Cassava Succeed With Its Alzheimer’s Drug, When So Many Have Failed? – The Motley Fool
Alzheimer’s research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about…
Cassava Sciences(NASDAQ:SAVA) is like any other unprofitable biotech — it has a drug in clinical trials, and its investors are hoping the drug works so they can make a lot of money. What makes Cassava really interesting is that it’s zigging where Big Pharma…
Continue Reading
-
Business24 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Noosa News23 hours agoThe Almond Ashes sees Australia and India mix business and cricket
-
General23 hours agoUK PM ready to ‘shelter’ businesses from tariff storm
-
General23 hours agoWhy do states and territories have different school holidays?